Research programme: doxorubicin oral - Athenex

Drug Profile

Research programme: doxorubicin oral - Athenex

Alternative Names: Doxorubicin + HM-30181A; Oral doxorubicin - Athenex

Latest Information Update: 06 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Athenex
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 09 Mar 2015 Doxorubicin oral licensed to Kinex Pharmaceuticals in India
  • 22 Oct 2013 Doxorubicin oral licensed to Kinex Pharmaceuticals in Malaysia, Thailand, Vietnam, the Philippines and Indonesia
  • 01 Aug 2013 Preclinical trials in Cancer in Hong Kong (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top